KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) R&D In Process (2025)

CRISPR Therapeutics AG (CRSP) has disclosed R&D In Process for 1 consecutive years, with $96.3 million as the latest value for Q2 2025.

  • Quarterly R&D In Process changed N/A to $96.3 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $96.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $96.3 million for FY2025, N/A changed from the prior year.
  • R&D In Process hit $96.3 million in Q2 2025 for CRISPR Therapeutics AG.
  • In the past five years, R&D In Process ranged from a high of $96.3 million in Q2 2025 to a low of $96.3 million in Q2 2025.